The parade of new pharma board chairs is growing longer. GlaxoSmithKline is reportedly eyeing Sir Philip Hampton, now chairman at Royal Bank of Scotland, to take up where Sir Christopher Gent leaves off next year, according to the London Evening Standard.
When ChemoCentryx reported last month that its Crohn's disease drug vercirnon (GSK1605786) failed the first of four Phase III trials mounted by GlaxoSmithKline, the biotech said it was awaiting word from the pharma giant on its future development plans.
Friday, the agency dubbed Arzerra a "breakthrough therapy," a coveted designation that puts the leukemia drug into the fast lane for first-line use. And today, the FDA put GSK's new melanoma duo, Tafinlar and Mekinist, on its priority review track as a combination cocktail.
The FDA will fast-track review of the drug for use with an alkylator-based therapy for the patients with chronic lymphocytic leukaemia (CLL) who have not received any previous treatment and are inappropriate for fludarabine-based therapy.
GlaxoSmithKline has been having a year for the record book. And that's not entirely a good thing.
Just after the FDA published draft guidance that would make it easier for generic drugmakers to produce copycat versions of Glaxo's Advair, the agency assembled a panel of experts who voted to endorse a new lung therapy from the British drugmaker. But even with the bit of good news, GSK still has its hands full.
GlaxoSmithKline and Theravance have nailed down a solid majority of FDA panel votes in favor of marketing their new COPD therapy Anoro Ellipta. The outside experts voted 11 to 2 this afternoon to endorse the therapy, opening the door to the first of several new drug that will likely wind up duking it out in a tough fight for market share.
For a long time, the difficulty of replicating GlaxoSmithKline's Advair has put off would-be copycats. Despite losing patent protection in 2010, the asthma treatment remains Glaxo's best-selling product. But now, the FDA has released new draft guidance that could change all that.
The two companies announced the deal for Lucozade and Ribena Monday, with a heftier price tag than the $1.6 billion Reuters first reported last week. As the news service notes, Suntory can well afford the transaction and is happy to do so, as both brands are well-established in Britain.
Once again, GlaxoSmithKline has the U.S. Justice Department on its tail. Prosecutors are investigating bribery allegations that Glaxo faces in China, trying to determine whether the drugmaker violated U.S. law.